Document Type
Article
Publication Date
3-20-2024
Identifier
DOI: 10.3390/genes15030379
Abstract
Beta adrenergic receptor antagonists, known as beta blockers, are one of the most prescribed medications in both pediatric and adult cardiology. Unfortunately, most of these agents utilized in the pediatric clinical setting are prescribed off-label. Despite regulatory efforts aimed at increasing pediatric drug labeling, a majority of pediatric cardiovascular drug agents continue to lack pediatric-specific data to inform precision dosing for children, adolescents, and young adults. Adding to this complexity is the contribution of development (ontogeny) and genetic variation towards the variability in drug disposition and response. In the absence of current prospective trials, the purpose of this comprehensive review is to illustrate the current knowledge gaps regarding the key drivers of variability in beta blocker drug disposition and response and the opportunities for investigations that will lead to changes in pediatric drug labeling.
Journal Title
Genes (Basel)
Volume
15
Issue
3
MeSH Keywords
Child; Humans; Adolescent; Young Adult; Adrenergic beta-Antagonists; Genetic Variation
Keywords
beta-blockers; pediatrics; pharmacogenomics
Recommended Citation
Walton M, Wagner JB. Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults. Genes (Basel). 2024;15(3):379. Published 2024 Mar 20. doi:10.3390/genes15030379
Comments
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Publisher's Link: https://www.mdpi.com/2073-4425/15/3/379
Grants and funding